Forte Biosciences, Inc. (FBRX) Shares Positive FB102 Phase 1b Vitiligo Study Results
Forte Biosciences, Inc. (FBRX) has announced positive results from its FB102 Phase 1b study focused on vitiligo, detailing the mechanism of action involved.
Editorial Staff about 14 hours ago